Resecabtagene autoleucel - Cabaletta Bio
Alternative Names: CABA-201; rese-celLatest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator Cabaletta Bio
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Myasthenia gravis; Myositis; Systemic lupus erythematosus; Systemic scleroderma
- Phase I Pemphigus vulgaris
- Preclinical Multiple sclerosis
Most Recent Events
- 13 Jan 2025 Preclinical trials in Multiple sclerosis in USA (Parenteral), before January 2025
- 13 Jan 2025 Cabaletta Bio announces intention to meet with the US FDA to discuss potential registrational trial designs for resecabtagene autoleucel in first half of 2025
- 13 Jan 2025 Resecabtagene autoleucel - Cabaletta Bio receives Fast Track designation for Multiple sclerosis [Parenteral] in USA